Physician profile
Christopher Alan Jones
NPI 1639162092
$7,585.99
in general payments reported to CMS, 2019-2025
24 companies · $1,621 in 2025
The $1,621 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,316 · 2022: $1,458 · 2023: $1,903 · 2024: $1,288 · 2025: $1,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,212 · Consulting Fee: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,212.18 |
| Consulting Fee | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,316.25 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $996.14 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $756.00 | 2021-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $718.84 | 2021-2025 | Jardiance |
| Biosense Webster, INC. | $600.00 | 2023 | Carto 3 |
| Novo Nordisk INC | $523.03 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Alnylam Pharmaceuticals INC. | $475.62 | 2022-2025 | Onpattro |
| Scpharmaceuticals INC. | $422.09 | 2024-2025 | |
| Boston Scientific Corporation | $304.15 | 2023-2025 | Bodyguardian, Cds - Mct/Cem Monitoring |
| Amgen INC. | $276.55 | 2021-2025 | Repatha, Repatha |
| Medtronic, INC. | $215.92 | 2021-2024 | Linq II, Mycarelink, Azure Xt Dr Mri Surescan |
| Bayer Healthcare Pharmaceuticals INC. | $183.48 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $174.93 | 2021-2025 | Wainua, Farxiga |
| Lexicon Pharmaceuticals, INC. | $155.45 | 2023-2024 | Inpefa |
| Abbott Laboratories | $109.28 | 2022-2025 | Cardiomems, Gallant, Aveir |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $71.15 | 2025 | Attruby |
| Leo Pharma INC. | $62.53 | 2023-2025 | Adbry |
| Esperion Therapeutics, INC. | $62.46 | 2021-2024 | Nexletol |
| Lundbeck LLC | $42.18 | 2021 | |
| Sanofi-Aventis U.S. LLC | $41.96 | 2021 | |
| Cleerly, INC. | $34.24 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Pfizer INC. | $20.15 | 2021 | |
| Lilly USA, LLC | $15.00 | 2023 | Mounjaro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $8.59 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.